| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Nifursemizone targets protozoan parasites, particularly Trypanosoma species. As a nitrofuran antimicrobial agent, its mechanism likely involves reductive activation of the nitro group by microbial enzymes, generating reactive intermediates that damage DNA and other cellular components. The compound is an antiprotozoal agent used for treating trypanosomiasis. Its mechanism of action is characteristic of the nitrofuran class.
|
|---|---|
| ln Vitro |
In vitro, Nifursemizone demonstrates antiprotozoal activity against Trypanosoma species. As a nitrofuran antimicrobial, it inhibits protozoan growth. The compound's antiprotozoal activity has been characterized in various in vitro susceptibility tests. It is used in antiparasitic research. Further in vitro studies have evaluated its spectrum of activity against various protozoan parasites.
|
| ln Vivo |
In vivo, Nifursemizone is an antiparasitic drug primarily used for treating trypanosomiasis in animals. It is a 5-nitrofuran antiprotozoal agent. The compound has been used in veterinary medicine. Its efficacy against Trypanosoma infections has been demonstrated. The compound is intended for research use only and not for human use.
|
| Enzyme Assay |
Nifursemizone antiprotozoal susceptibility assays involve determining minimum inhibitory concentrations (MIC) against Trypanosoma species and other protozoan parasites. Parasites are cultured in appropriate media and treated with the compound at varying concentrations. Parasite growth is monitored by counting or metabolic assays. MIC values are determined using standard methods. For mechanism studies, nitroreductase activity and DNA damage may be assessed. Assays are performed with appropriate positive controls such as known antiprotozoal agents.
|
| Cell Assay |
Nifursemizone cell-based assays are conducted in protozoan cultures and mammalian cell lines. Protozoa are cultured in appropriate media and treated with the compound at varying concentrations. Antiprotozoal activity is assessed by measuring parasite growth inhibition. For mammalian cell studies, cell viability is assessed by standard assays to evaluate selectivity. Experiments are performed in triplicate with appropriate positive (e.g., known antiprotozoal agents) and negative (vehicle) controls.
|
| Animal Protocol |
Nifursemizone in vivo studies are conducted in animal models of trypanosomiasis. Animals are infected with Trypanosoma species and treated with Nifursemizone via oral administration or injection. Parasitemia is monitored by blood smears. Survival rates and clinical signs are monitored. For pharmacokinetic studies, blood samples are collected for analysis. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biochemical analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Nifursemizone (MW 226.19 g/mol, C8H10N4O4) is a nitrofuran antiprotozoal agent. It is also known as Etafurazone or NF161. The compound is soluble in DMSO and other organic solvents. It is stable under recommended storage conditions. Nifursemizone is an antiparasitic drug used in veterinary research. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
Nifursemizone is generally well-tolerated at therapeutic doses used in veterinary medicine. The compound is a nitrofuran antiprotozoal agent with established safety profiles in animals. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| Additional Infomation |
Nifursemizone (Etafurazone, NF161) is an antiprotozoal drug belonging to the nitrofuran class of antimicrobial agents. It is primarily used for treating trypanosomiasis in animals, targeting Trypanosoma species. The compound is a 5-nitrofuran antiprotozoal agent. Its molecular formula is C8H10N4O4 with a molecular weight of 226.19 g/mol. All applications are limited to non-human research use.
|
| Molecular Formula |
C8H10N4O4
|
|---|---|
| Molecular Weight |
226.1894
|
| Exact Mass |
226.07
|
| CAS # |
5579-89-5
|
| PubChem CID |
9562728
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.47g/cm3
|
| Boiling Point |
378.3ºC at 760mmHg
|
| Flash Point |
182.6ºC
|
| Index of Refraction |
1.614
|
| LogP |
2.145
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
16
|
| Complexity |
301
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCN(C(=O)N)/N=C/C1=CC=C(O1)[N+](=O)[O-]
|
| InChi Key |
JGPNCLKRECLYTO-BJMVGYQFSA-N
|
| InChi Code |
InChI=1S/C8H10N4O4/c1-2-11(8(9)13)10-5-6-3-4-7(16-6)12(14)15/h3-5H,2H2,1H3,(H2,9,13)/b10-5+
|
| Chemical Name |
1-ethyl-1-[(E)-(5-nitrofuran-2-yl)methylideneamino]urea
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20.83 mg/mL (~92.09 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (9.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4211 mL | 22.1053 mL | 44.2106 mL | |
| 5 mM | 0.8842 mL | 4.4211 mL | 8.8421 mL | |
| 10 mM | 0.4421 mL | 2.2105 mL | 4.4211 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
